Terms: = Pancreatic cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Diagnosis
9 results:
1. Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
Corti F; Brizzi MP; Amoroso V; Giuffrida D; Panzuto F; Campana D; Prinzi N; Milione M; Cascella T; Spreafico C; Randon G; Oldani S; Leporati R; Scotto G; Pulice I; Stocchetti BL; Porcu L; Coppa J; Di Bartolomeo M; de Braud F; Pusceddu S
BMC Cancer; 2023 Sep; 23(1):908. PubMed ID: 37752423
[TBL] [Abstract] [Full Text] [Related]
2. vegfr2 targeted microbubble-based ultrasound molecular imaging improving the diagnostic sensitivity of microinvasive cervical cancer.
Zhong J; Su M; Jiang Y; Huang L; Chen Y; Huang Z; Zhang X
J Nanobiotechnology; 2023 Jul; 21(1):220. PubMed ID: 37438780
[TBL] [Abstract] [Full Text] [Related]
3. Peripancreatic paraganglioma: Lesson from a round table.
Petrelli F; Fratini G; Sbrozzi-Vanni A; Giusti A; Manta R; Vignali C; Nesi G; Amorosi A; Cavazzana A; Arganini M; Ambrosio MR
World J Gastroenterol; 2022 Jun; 28(21):2396-2402. PubMed ID: 35800185
[TBL] [Abstract] [Full Text] [Related]
4. Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the Treatment of cancer: A Review.
Unnisa A; Chettupalli AK; Hussain T; Kamal MA
Anticancer Agents Med Chem; 2022; 22(20):3370-3381. PubMed ID: 35400324
[TBL] [Abstract] [Full Text] [Related]
5. Comprehensive Analysis of Immunoinhibitors Identifies LGALS9 and TGFBR1 as Potential Prognostic Biomarkers for pancreatic cancer.
Fan Y; Li T; Xu L; Kuang T
Comput Math Methods Med; 2020; 2020():6138039. PubMed ID: 33062039
[TBL] [Abstract] [Full Text] [Related]
6. Molecular Analysis of Vascular Endothelial Growth Factor (VEGF) Receptors in EUS-guided Samples Obtained from Patients with pancreatic Adenocarcinoma.
Costache MI; Iordache S; Costache CA; Dragos E; Dragos A; Saftoiu A
J Gastrointestin Liver Dis; 2017 Mar; 26(1):51-57. PubMed ID: 28338114
[TBL] [Abstract] [Full Text] [Related]
7. Roles of serum and biliary CEA, CA19-9, vegfr3, and TAC in differentiating between malignant and benign biliary obstructions.
Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
[TBL] [Abstract] [Full Text] [Related]
8. Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors.
Kulke MH; Bendell J; Kvols L; Picus J; Pommier R; Yao J
J Hematol Oncol; 2011 Jun; 4():29. PubMed ID: 21672194
[TBL] [Abstract] [Full Text] [Related]
9. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
[TBL] [Abstract] [Full Text] [Related]
